Mental and Behavioral Health

Zuranolone, a fast-acting neuroactive steroid that can take effect in 14 days, has been assigned a PDUFA action date of Aug. 5, 2023 by the FDA. It can be used to treat patients with major depressive disorder and postpartum depression.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

There may not be a diagnosis for ‘New Year Depression,’ but about 10% to 20% of individuals in the US may get a milder form of these winter blues.

A recent study found a rise in the prevalence of antipsychotic prescriptions among pediatric patients and noted which antipsychotics were most commonly used for specific indications.

A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.

Pharmacists can use a variety of tools to foster resilience and prevent burnout.

A recent study highlights the significant frequency of the adverse effect.

Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.

When dealing with marginalized and underserved populations, it is important to understand barriers to care and why they exist.

With increasing use of telehealth, patients need access to resources that let them get the most out of the experience.

Social support and education may be the solution.

Online portals are accessible via tablet or computer and can streamline the mental health screening process.

Cost savings were not associated with an increase in adverse drug events.

Low-income subsidies can eliminate much of the out-of-pocket costs that patients must pay.

We may be one step closer to nonprescription naloxone.

ADHD is an all-day affair, and treating it in an adult population can be difficult.

More and more women are being diagnosed with ADHD in adulthood. What's behind this increase?

Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.

Several drugs with novel mechanisms of action have been put on the pathway for speedier approval decisions by the FDA. Phase 2 and 3 trials are underway.

Make mental health a priority.

In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.

A new—cough, cough—combination treatment for depression. Researchers performed an RCT of dextromethorphan-bupropion in major depressive disorder.

Risk of suicide attempt is higher among adults, women.

The causes of burnout in pharmacy are multifactorial. The solutions need to be as well.

What are the long term psychiatric and neuropsychiatric complications of COVID-19?

A recent review suggests that atomoxetine can reduce symptoms of anxiety in children and adolescents with ADHD.

Opioid use disorder—how can we battle the epidemic of overdoses?

Lack of blood clotting may afford some protection against common cardiovascular disease events, such as ischemic stroke.

Despite mixed data, there are some psychopharmacological options for treating PTSD.

Further evidence-based antidepressant treatments are needed for children and adolescents with depression.